Methylphenidate HCl is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Methylphenidate HCl is currently available in 27mg extended-release tablets. Methylphenidate HCl will be available in 36mg and 54mg dosage strengths in the first quarter of 2013. Mallinckrodt also plans to submit a supplement to its approved abbreviated new drug application for Methylphenidate HCl 18mg in the first quarter of 2013.
For more information call (888) 744-1414 or visit www.mallinckrodt.com.